Archived
Luminex magnetic carboxylated microsphere beads, or equivalent
Overview
- Response deadline
- 3:30 PM CDT
- Posted
- June 9, 2026
- Notice type
- Combined Synopsis/Solicitation
- Set-aside
- No Set aside used
- NAICS
- 325413: In-Vitro Diagnostic Substance Manufacturing
- Agency
- Department of Health and Human ServicesFOOD AND DRUG ADMINISTRATION
Notice details
- Office
- FDA OFFICE OF ACQ GRANT SVCS
- Last updated
- Oct 30, 2026
- First published
- Last updated on SAM.gov
Identifiers
- Solicitation number
- 75F40126Q134073
- Notice ID
- bfe1f1d45d8844aeaa49138e8d75bb63
Description
See attached solicitatin/RFQ for Luminex magnetic carboxylated microsphere beads, or equivalent.
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Contracting Officer
Primary Contact
Documents
Lifecycle
- 3Version 3Sources SoughtArchived
Luminex magnetic carboxylated microsphere beads, or equivalent
- 6Version 6Combined Synopsis/SolicitationArchivedCurrent
Type changed from Sources Sought to Combined Synopsis/Solicitation
Luminex magnetic carboxylated microsphere beads, or equivalent
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Please see attached Combined Synopsis/Solicitation. See attached estimated quantities and Questions and Answers. | - | Combined Synopsis | 11/18/2026 |
(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a separate written solicitation will not be issued. (ii) The solicitation number is 75N98027Q00027. This solicitation is issued as a Notice of Intent (NOI) for a non-competitive combined synopsis/solicitation to award a contract or purchase order without providing for full and open competition (including brand-name, if applicable). This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii). The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a firm-fixed-price purchase order on a non-competitive basis to Integrated DNA Technologies, Inc. (IDT), 1710 Commercial Park, Coralville, IA 52241, for custom-designed ArcherDX VariantPlex Next-Generation Sequencing (NGS) target-enrichment library preparation kits. Integrated DNA Technologies, Inc. is the sole owner, manufacturer, and distributor of the proprietary ArcherDX VariantPlex Anchored Multiplex PCR (AMP) chemistry, which has been utilized by the NHLBI Hematology Branch since 2019 to perform error-correcting sequencing (ECS) and is required to maintain scientific continuity, prevent technical batch effects across longitudinal patient cohorts, and ensure compatibility with the laboratory¿s established Archer Analysis bioinformatics pipeline. All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2026-01, effective 03/13/2026. (iv) The associated NAICS code is 325413 (In-Vitro Diagnostic Substance Manufacturing) and the small business size standard is 1,250 employees. This requirement is not set aside for small business. | - | Combined Synopsis | 11/05/2026 |
NOTICE OF INTENT – SOLE-SOURCE ACQUISITION Notice No.: The National Institutes of Health (NIH), National Institute of Environmental Health Sciences (NIEHS), intends to award a Firm-Fixed-Price Purchase Order to Creative Biolab Inc. for culture all cells and differentiate them, expand their cell populations to more than 20 million, collect them, verify cell count, and send them back to us. Description of the Requirement The primary objective of this study is to sequence and analyze the 4q35 locus on Chromosome 4 for several years. This locus is a gene-poor and extremely long (>100K) region of DNA that consists of many repetitive sequences which makes sequencing and analysis extremely difficult. To sequence this locus using Nanopore Sequencing technology. To expand the number of samples for our experiment, we looked for a company that can handle numerous cell lines and follow the protocol that we provide. Creative Biolabs is the only company/research institute that has been able to perform differentiation within 3 months and has the ability to follow our protocol with numerous cell lines. Justification for the Proposed Sole-Source Acquisition The Government intends to solicit from a single source pursuant to FAR 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements. Only Creative Biolabs was willing to follow our exact protocol and had the logistical capacity to handle the large number of cell lines that we need to analyze, which is vital to research at the National Institute of Environmental Health Sciences. Response Information This notice is not a request for competitive quotations or proposals. However, interested parties that believe they can meet the Government's requirements may submit a capability statement demonstrating their ability to provide the required preventive maintenance and remedial repair services for the specified instrument and meet all applicable technical and operational requirements. The Government will review timely submissions to determine whether another responsible source is capable of satisfying the requirement and whether a competitive acquisition is appropriate. The Government anticipates making an award approximately five (5) calendar days after the closing date of this notice, unless the Government determines that another responsible source can satisfy the requirement. Capability statements must be submitted electronically to verne.griffin@nih.gov no later than 9:00 a.m. EDT on November 13, 2026. Please reference Notice No. 75N98027Q00053 in the subject line of the submission. | - | Pre-Solicitation | 11/12/2026 |
Redacted J&A posted in accordance with RFO 6.301 | - | Sole Source / J&A | Open |
See attached Notice of Intent to Sole Source HT941027N0010 | - | Special Notice | 11/23/2026 |
Additional Details
Solicitation Number
75F40126Q134073
Archive Date
Jul 1, 2026
Office Address
Rockville, MD, 20852